N-glycosylation of carnosinase influences protein secretion and enzyme activity: Implications for hyperglycemia

Diabetes

Volumn 59, Issue 8, 2010, Pages 1984-1990

  Riedl, Eva ^a   Koeppel, Hannes ^a   Pfister, Frederick ^a   Peters, Verena ^b   Sauerhoefer, Sibylle ^a   Sternik, Paula ^a   Brinkkoetter, Paul ^a,c   Zentgraf, Hanswalter ^d   Navis, Gerjan ^e   Henning, Robert H ^e   Van Den Born, Jacob ^e   Bakker, Stephan J L ^d   Janssen, Bart ^b   Van Der Woude, Fokko J ^a   Yard, Benito A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOACYLHISTIDINE DIPEPTIDASE; CARNOSINE; GLUCOSE; N ACETYLGALACTOSAMINE; PROTEINASE; TUNICAMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ARTICLE; CELL STRAIN COS7; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; ENZYME MODIFICATION; ENZYME SYNTHESIS; FEMALE; GENETIC POLYMORPHISM; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN SECRETION;

ADULT; AGE OF ONSET; AGED; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DIPEPTIDASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLYCOSYLATION; HEXOSAMINES; HUMANS; HYPERGLYCEMIA; MIDDLE AGED; MUTAGENESIS, SITE-DIRECTED; POLYMORPHISM, GENETIC; REFERENCE VALUES; TRANSFECTION; TUNICAMYCIN;

EID: 77955392475     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-0868     Document Type: Article

References (38)

1. Ritz E, Rychlík I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
3. Parving HH. Hypertension Optimal Treatment (HOT) Trial. Lancet 1998; 352:574-575
4. Janssen B, Hohenadel D, Brinkkoetter P, Peters V, Rind N, Fischer C, Rychlik I, Cerna M, Romzova M, de Heer E, Baelde H, Bakker SJ, Zirie M, Rondeau E, Mathieson P, Saleem MA, Meyer J, Koppel H, Sauerhoefer S, Bartram CR, Nawroth P, Hammes HP, Yard BA, Zschocke J, van der Woude FJ. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 2005;54: 2320-2327
5. Riedl E, Koeppel H, Brinkkoetter P, Sternik P, Steinbeisser H, Sauerhoefer S, Janssen B, van der Woude F, Yard B. A CTG polymorphism in the CNDP1 gene determines the secretion of serum carnosinase in Cos-7 transfected cells. Diabetes 2007;56:2410-2413
6. Sauerhofer S, Yuan G, Braun GS, Deinzer M, Neumaier M, Gretz N, Floege J, Kriz W, van der Woude F, Moeller MJ. L-carnosine, a substrate of carnosinase-1, influences glucose metabolism. Diabetes 2007;56:2425-2432
7. Hipkiss A, Preston J, Himsworth D, Worthington V, Keown M, Michaelis J, Lawrence J, Mateen A, Allende L, Eagles P, Abbott N. Pluripotent protective effects of carnosine, a naturally occurring dipeptide. Ann N Y Acad Sci 1998;854:37-53
8. Fouad A, El-Rehany M, Maghraby H. The hepatoprotective effect of carnosine against ischemia/reperfusion liver injury in rats. Eur J Pharmacol 2007;572:61-68
9. Kurata H, Fujii T, Tsutsui H, Katayama T, Ohkita M, Takaoka M, Tsuruoka N, Kiso Y, Ohno Y, Fujisawa Y, Shokoji T, Nishiyama A, Abe Y, Matsumura Y. Renoprotective effects of l-carnosine on ischemia/reperfusion-induced renal injury in rats. J Pharmacol Exp Ther 2006;319:640-647
10. Rajanikant G, Zemke D, Senut M, Frenkel M, Chen A, Gupta R, Majid A. Carnosine is neuroprotective against permanent focal cerebral ischemia in mice. Stroke 2007;38:3023-3031
11. Bowden DW, Colicigno CJ, Langefeld CD, Sale MM, Williams A, Anderson PJ, Rich SS, Freedman BI. A genome scan for diabetic nephropathy in African Americans. Kidney Int 2004;66:1517-1526
12. Freedman BI, Hicks PJ, Sale MM, Pierson ED, Langefeld CD, Rich SS, Xu J, McDonough C, Janssen B, Yard BA, van der Woude FJ, Bowden DW. A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans. Nephrol Dial Transplant 2007;22:1131-1135
13. Wanic K, Placha G, Dunn J, Smiles A, Warram JH, Krolewski AS. Exclusion of polymorphisms in carnosinase genes (CNDP1 and CNDP2) as a cause of diabetic nephropathy in type 1 diabetes: results of large case-control and follow-up studies. Diabetes 2008;57:2547-2551
14. Bakker SJ, Alkhalaf A, Tarnow L, Navis G. Re: Exclusion of polymorphisms in carnosinase genes (CNDP1 and CNDP2) as a cause of diabetic nephropathy in type 1 diabetes: results of large case-control and follow-up studies. Diabetes 2008;57:e16; author reply e17
15. Molinari M. N-glycan structure dictates extension of protein folding or onset of disposal. Nat Chem Biol 2007;3:313-320
16. Broschat KO, Gorka C, Page JD, Martin-Berger CL, Davies MS, Huang Hc HC, Gulve EA, Salsgiver WJ, Kasten TP. Kinetic characterization of human glutamine-fructose-6-phosphate amidotransferase I: potent feedback inhibition by glucosamine 6-phosphate. J Biol Chem 2002;277:14764-14770
17. Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, Dennis JW. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 2007;129:123-134
18. Sasai K, Ikeda Y, Fujii T, Tsuda T, Taniguchi N. UDP-GlcNAc concentration is an important factor in the biosynthesis of beta1,6-branched oligosaccharides: regulation based on the kinetic properties of N-acetylglucosaminyltransferase V. Glycobiology 2002;12:119-127
19. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625
20. Bar-On H, Nesher G, Teitelbaum A, Ziv E. Dolichol-mediated enhanced protein N-glycosylation in experimental diabetes - a possible additional deleterious effect of hyperglycemia. J Diabetes Complications 1997;11: 236-242
21. Teufel M, Saudek V, Ledig J, Bernhardt A, Boularand S, Carreau A, Cairns N, Carter C, Cowley D, Duverger D, Ganzhorn A, Guenet C, Heintzelmann B, Laucher V, Sauvage C, Smirnova T. Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem 2003;278:6521-6531
22. Antenos M, Stemler M, Boime I, Woodruff TK. N-linked oligosaccharides direct the differential assembly and secretion of inhibin alpha- and betaA-subunit dimers. Mol Endocrinol 2007;21:1670-1684
23. Li Y, Yang X, Nguyen AH, Brockhausen I. Requirement of N-glycosylation for the secretion of recombinant extracellular domain of human Fas in HeLa cells. Int J Biochem Cell Biol 2007;39:1625-1636
24. Zhou W, Tsai HM. N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity. Blood 2009;113:929-935
25. Olivari S, Molinari M. Glycoprotein folding and the role of EDEM1, EDEM2 and EDEM3 in degradation of folding-defective glycoproteins. FEBS Lett 2007;581:3658-3664
26. Ellgaard L, Molinari M, Helenius A. Setting the standards: quality control in the secretory pathway. Science 1999;286:1882-1888
27. Ito K, Seri A, Kimura F, Matsudomi N. Site-specific glycosylation at Asn-292 in ovalbumin is essential to efficient secretion in yeast. J Biochem 2007;141:193-199
28. Pradere JP, Tarnus E, Gres S, Valet P, Saulnier-Blache JS. Secretion and lysophospholipase D activity of autotaxin by adipocytes are controlled by N-glycosylation and signal peptidase. Biochim Biophys Acta 2007;1771:93-102
29. Gladysheva IP, King SM, Houng AK. N-glycosylation modulates the cell-surface expression and catalytic activity of corin. Biochem Biophys Res Commun 2008;373:130-135
30. Pacheco B, Maccarana M, Goodlett DR, Malmstrom A, Malmstrom L. Identification of the active site of DS-epimerase 1 and requirement of N-glycosylation for enzyme function. J Biol Chem 2009;284:1741-1747
31. Wendt T, Tanji N, Guo J, Hudson B, Bierhaus A, Ramasamy R, Arnold B, Nawroth P, Yan S, D'Agati V, Schmidt A. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003;14:1383-1395
32. Bierhaus A, Hofmann M, Ziegler R, Nawroth P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998;37:586-600
33. Bar-On H, Nesher G, Teitelbaum A, Ziv E. Dolichol-mediated enhanced protein N-glycosylation in experimental diabetes-a possible additional deleterious effect of hyperglycemia. J Diabetes Complications 1997;11: 236-242
34. Berry E, Ziv E, Bar-On H. Protein and glycoprotein synthesis and secretion by the diabetic liver. Diabetologia 1980;19:535-540
35. Berry E, Ziv E, Bar-On H. Lipoprotein secretion by isolated perfused livers from streptozotocin-diabetic rats. Diabetologia 1981;21:402-408
36. Jones J, Krag SS, Betenbaugh MJ. Controlling N-linked glycan site occupancy. Biochim Biophys Acta 2005;1726:121-137
37. Lenney JF, George RP, Weiss AM, Kucera CM, Chan PW, Rinzler GS. Human serum carnosinase: characterization, distinction from cellular carnosinase, and activation by cadmium. Clin Chim Acta 1982;123:221-231
38. Peters V, Kebbewar M, Jansen EW, Jakobs C, Riedl E, Koeppel H, Frey D, Adelmann K, Klingbeil K, Mack M, Hoffmann GF, Janssen B, Zschocke J, Yard BA. Relevance of allosteric conformations and homocarnosine concentration on carnosinase activity. Amino Acids 2010;38:1607-1615